Hermetica Superfood Encyclopedia
The Short Answer
Isaridin E is a cyclohexadepsipeptide containing valine, tyrosine or phenylalanine, and proline residues that suppresses the TLR4/NF-κB signaling cascade to reduce pro-inflammatory cytokine expression, adhesion molecule production, and vascular hyperpermeability. Preclinical data from LPS-induced murine endotoxemia models demonstrate dose-dependent attenuation of NF-κB (p65) phosphorylation in aortic and lung tissues, reduced inflammatory cell infiltration, and preserved tissue integrity, though no human clinical trials have yet been conducted.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordisaridin E benefits
Isaridin E — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Isaridin E suppresses TLR4/NF-κB signaling in lipopolysaccharide-stimulated human umbilical vein endothelial cells (HUVECs), reducing pro-inflammatory cytokine expression and monocyte adhesion to the endothelial surface in a concentration-dependent manner.
**Vascular Protective Effects**
In murine LPS-induced endotoxemia, the compound attenuated vascular hyperpermeability and preserved structural integrity of aortic tissue, suggesting a potential role in protecting endothelial barrier function during systemic inflammatory states.
**Anti-Thrombotic Potential**
By reducing monocyte-endothelial adhesion and suppressing adhesion molecule upregulation, isaridin E may interfere with early thrombogenic processes at the vascular wall, though direct platelet inhibition data remain limited to preclinical models.
**Neutrophil Activity Suppression**
Isaridin E attenuates neutrophil-mediated oxidative stress by suppressing formyl-methionyl-leucyl-phenylalanine (FMLP)-induced superoxide anion release, potentially reducing collateral tissue damage during acute inflammatory responses.
**Antiplasmodial Activity**
Preliminary data indicate isaridin E possesses antiplasmodial properties, positioning it as a candidate scaffold for antimalarial drug development, though mechanism and potency data in this context remain sparse.
**Antibacterial Properties**: Structurally related isaridin congeners (e
g., isaridin C1) demonstrate antibacterial activity against Escherichia coli at minimum inhibitory concentrations of approximately 8 μg/mL, suggesting the isaridin class may have broad antimicrobial utility.
**Pulmonary Tissue Preservation**
In vivo endotoxemia studies show that isaridin E reduces inflammatory cell infiltration in lung tissue and attenuates TLR4 expression in pulmonary tissue, indicating potential relevance in acute lung injury models.
Origin & History
Natural habitat
Isaridin E is a secondary metabolite isolated from the marine-derived fungus Amphichorda felina (synonymously referred to as Beauveria felina in earlier literature), which inhabits oceanic and coastal environments. The fungus is typically recovered from marine sediments, seawater, or associated marine organisms, and is cultivated under controlled laboratory fermentation conditions for research purposes. No traditional agricultural or wild-harvesting practices exist for this organism, as it was first characterized and studied within modern marine natural products research programs.
“Isaridin E has no history of use in any traditional medicine system, as it was identified through modern marine natural products chemistry and has not been known to pre-industrial or indigenous cultures. The compound was first isolated and structurally characterized from Amphichorda felina as part of systematic screening programs aimed at discovering bioactive secondary metabolites from marine-derived fungi, an active area of pharmaceutical research that expanded significantly in the late 20th and early 21st centuries. The fungal genus Beauveria (with which Amphichorda felina was historically associated) has a separate entomopathogenic history in biological pest control, but this connection does not extend to traditional medicinal use of isaridin compounds. The isaridin designation itself reflects a naming convention within marine natural products taxonomy and carries no cultural or ethnopharmacological heritage.”Traditional Medicine
Scientific Research
The entirety of published evidence for isaridin E consists of early-stage preclinical research, with no human clinical trials registered or completed as of the most recent literature (2024). The highest-quality available data derive from in vitro studies using LPS-stimulated HUVECs and in vivo murine endotoxemia models, demonstrating dose-dependent anti-inflammatory and vascular protective effects; however, these model systems have well-recognized limitations in predicting human pharmacological responses. A 2024 study confirmed isaridin E's efficacy in attenuating TLR4/NF-κB activation in animal tissues and proposed the compound as a novel marine metabolite with therapeutic potential, while explicitly noting that preclinical-to-clinical translation requires further pharmacokinetic, toxicological, and safety characterization. Related isaridin congeners have been evaluated for antibacterial activity (isaridin C1, MIC 8 μg/mL against E. coli) and antiplasmodial activity, collectively strengthening the biological plausibility of the isaridin class but not substituting for isaridin E-specific clinical data.
Preparation & Dosage
Traditional preparation
**Research Solvent Preparation**
Isaridin E is dissolved in dimethyl sulfoxide (DMSO) at concentrations below 0.1% for in vitro and in vivo experimental use; this preparation method is not suitable for human supplementation.
**Laboratory Isolation**
The compound is extracted from fermentation cultures of Amphichorda felina using standard marine natural products protocols, followed by chromatographic purification and structural confirmation via NMR spectroscopy and mass spectrometry.
**No Established Human Dose**
No clinically validated or supplementally standardized dose exists; all reported concentrations are experimental and derived from cell culture or murine model protocols.
**No Commercial Formulation**
Isaridin E is not available as a dietary supplement, pharmaceutical product, or standardized extract; it is accessible only as an analytical-grade research chemical from specialty suppliers.
**Standardization**
No standardization percentage, certificate of analysis benchmarks for consumer products, or regulatory monograph exists for isaridin E in any jurisdiction.
Nutritional Profile
Isaridin E is a pure cyclohexadepsipeptide secondary metabolite and does not constitute a food ingredient or nutritional source; it provides no meaningful macronutrient (protein, carbohydrate, lipid), micronutrient (vitamin, mineral), or caloric content in isolated form. The molecular structure incorporates amino acid-derived residues including valine (L- or D-configured), tyrosine or phenylalanine, and proline, which are constituents of the cyclic backbone rather than free nutritional amino acids available for metabolic assimilation. Bioavailability data for oral or systemic administration in humans are entirely absent, and no pharmacokinetic parameters (absorption, distribution, metabolism, excretion) have been published. The compound's ester bonds within the depsipeptide ring may render it susceptible to hydrolysis by gastrointestinal esterases, which could affect oral bioavailability, but this hypothesis has not been experimentally tested.
How It Works
Mechanism of Action
Isaridin E exerts its primary pharmacological effects through disruption of the Toll-like receptor 4 (TLR4)/Nuclear Factor kappa B (NF-κB) signaling axis, a central pathway in innate immune activation and vascular inflammation. Upon LPS stimulation, TLR4 activation normally drives phosphorylation of the p65 NF-κB subunit, triggering transcription of pro-inflammatory cytokines (including TNF-α, IL-6, and IL-1β) and adhesion molecules (such as ICAM-1 and VCAM-1); isaridin E suppresses this phosphorylation step in a concentration-dependent fashion, as confirmed in both HUVEC cell cultures and murine aortic and lung tissues. Additionally, the compound inhibits FMLP-induced superoxide anion generation in neutrophils, suggesting ancillary modulation of reactive oxygen species (ROS) production pathways independent of NF-κB. The cyclic depsipeptide scaffold—incorporating ester bonds alongside peptide bonds—likely confers conformational rigidity that facilitates selective binding interactions with upstream signaling intermediaries, though the precise molecular docking targets have not yet been crystallographically resolved.
Clinical Evidence
No human clinical trials have been conducted investigating isaridin E for any indication, including its putative anti-thrombotic or anti-inflammatory applications. All efficacy and mechanistic data originate from in vitro cell culture experiments and small-scale murine animal models, which preclude the calculation of clinically meaningful effect sizes, therapeutic windows, or patient-relevant outcome measures. Confidence in translational relevance is therefore very low by evidence-based medicine standards, and the compound should be regarded strictly as a research-stage molecule pending Phase I safety and pharmacokinetic studies. The 2024 preclinical publication represents the most advanced characterization to date, and no regulatory filings, investigational new drug applications, or commercial development pathways have been publicly disclosed.
Safety & Interactions
Comprehensive human safety data for isaridin E are entirely unavailable, as no clinical trials, observational studies, or formal toxicological evaluations in humans have been published; its safety profile in humans is therefore unknown and its use outside of controlled research settings cannot be recommended. Animal toxicity thresholds, no-observed-adverse-effect levels (NOAELs), and maximum tolerated doses have not been established in any published study, and the murine endotoxemia models used to date were not designed to capture adverse effect endpoints. No drug interaction data exist, meaning potential interactions with anticoagulants, anti-inflammatory agents, immunosuppressants, or other pharmacological classes cannot be assessed or predicted from available literature. Pregnancy, lactation, and pediatric safety are completely uncharacterized, and given the compound's biological activity on NF-κB and endothelial signaling pathways, use in these populations would carry undetermined and potentially significant risk.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Amphichorda felina cyclodepsipeptideBeauveria felina isaridin Ecyclohexadepsipeptide isaridin Emarine fungal depsipeptide E
Frequently Asked Questions
What is isaridin E and where does it come from?
Isaridin E is a cyclohexadepsipeptide—a cyclic molecule containing both peptide and ester bonds—isolated from the marine fungus Amphichorda felina, formerly classified as Beauveria felina. It is produced as a secondary metabolite during fungal fermentation and is found in marine sediment-associated fungal cultures rather than in terrestrial plants or traditional food sources. It is exclusively a research-stage compound with no commercial supplement form currently available.
What are the proven effects of isaridin E on inflammation?
In preclinical studies, isaridin E suppresses the TLR4/NF-κB signaling cascade in LPS-stimulated human umbilical vein endothelial cells, reducing pro-inflammatory cytokine expression and monocyte adhesion to the endothelial surface in a concentration-dependent manner. In murine LPS-induced endotoxemia models, it dose-dependently reduced phosphorylated p65 NF-κB activation in aortic and lung tissues, attenuated vascular hyperpermeability, and decreased lung inflammatory cell infiltration. However, these findings have not been replicated in human clinical trials, so their translational relevance remains unconfirmed.
Has isaridin E been tested in human clinical trials?
No human clinical trials for isaridin E have been published or registered as of the most recent available literature (2024). All existing efficacy data come from in vitro cell culture experiments and small-scale murine animal models, which represent early preclinical evidence only. The compound is not approved by any regulatory agency (including the FDA or EMA) and has no established pharmaceutical or supplemental formulation for human use.
Is isaridin E safe to take as a supplement?
Isaridin E cannot be considered safe for unsupervised human use because comprehensive toxicological data, adverse effect profiles, drug interaction assessments, and human pharmacokinetic parameters are entirely absent from the published literature. No maximum safe dose, no-observed-adverse-effect level, or human tolerability data have been established. It is currently only available as an analytical-grade research chemical dissolved in DMSO for laboratory use, and it should not be self-administered as a dietary supplement.
What other biological activities does isaridin E have besides anti-inflammation?
Beyond anti-inflammatory effects, isaridin E has demonstrated insecticidal activity, antiplasmodial (antimalarial) potential, and, as part of the broader isaridin compound class, antibacterial properties—with the related isaridin C1 showing activity against Escherichia coli at a minimum inhibitory concentration of 8 μg/mL. It also suppresses FMLP-induced superoxide anion release from neutrophils, suggesting a secondary antioxidant or immunomodulatory role. These activities position isaridin E as a multifunctional marine natural product scaffold, though each activity requires further dedicated investigation before therapeutic applications can be proposed.
Does isaridin E have effects beyond vascular and inflammatory responses?
Research indicates isaridin E may possess antimicrobial and antioxidant properties beyond its well-documented vascular protective effects, though these activities require further investigation in human systems. The compound's ability to modulate immune signaling pathways suggests potential applications in metabolic endotoxemia and related conditions, but additional studies are needed to characterize the full spectrum of its biological activities.
How does isaridin E compare to other endothelial-protective compounds in supplements?
Isaridin E differs from common vascular protectants like quercetin or resveratrol by specifically targeting TLR4/NF-κB signaling in endothelial cells, offering a distinct mechanism of action. While these other compounds work through general antioxidant pathways, isaridin E's anti-inflammatory effect on monocyte adhesion may provide more targeted vascular protection in endotoxemia-related conditions.
What populations might benefit most from isaridin E supplementation?
Individuals with chronic inflammatory conditions, metabolic endotoxemia, or vascular dysfunction may theoretically benefit from isaridin E's endothelial-protective effects, though clinical evidence in human populations remains limited. Those with conditions involving elevated lipopolysaccharide exposure or TLR4-mediated inflammation could be candidates, but supplementation should only be considered under professional guidance pending further human research.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w isaridin-e-amphichorda-felina curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
